Farsi Mir Mehrdad, Kamali Nematollah, Pourghasem Mohsen
Fatemeh Zahra Infertility and Health Reproductive Research Center, Babol University of Medical Sciences, Babol, Iran .
Department of Anatomical Sciences, Babol University of Medical Sciences, Babol, Iran.
Int J Mol Cell Med. 2013 Summer;2(3):99-109.
In Vitro Maturation (IVM) is a method that immature oocytes in antral follicles are extracted and matured in laboratry conditions. This review has attempted to provide the current knowledge and recent findings in in vitro maturation of oocytes and highlights the most important factors involved in this process. The review is based on literature reports and the author's experience. In IVM cycles, the time of administration of hCG is depending on the diameter of the largest follicle that has been determined to be about 10-12 mm to prevent the detrimental effect of dominant follicle (DF). Higher number of in vivo matured oocytes with dispersed cumulus cells (CC) pattern can be achieved by increasing the time of hCG injection up to 38 h. Growing of oocytes during the final hours of in vitro maturation has profound effect on the following outcome. Injection of IVM oocytes must be delayed at least 1 h after extrusion of the first polar body. IVM outcome shows that the pregnancy rate is low in pure immature oocytes except PCO(s) (Polycystic ovaries and Polycystic ovarian syndrome) cases. Furthermore, endometrial quality may have a crucial role in this respect after non hCG-triggered IVM. The formulation of different types of maturation media shows that they are generally supplemented with recombinant FSH and hCG. Taurine and calcium as unique components of blastocyst medium have been supposed to be valuable to IVM media. Pyruvate and adenosine triphosphate (ATP) and Epidermal Growth Factor (EGF) have been proposed as additives for maturation media. IVM is not a suitable treatment for women over 40 years. Different categories of patients could be candidate for IVM. Despite of old concept in low outcome and caution in IVM indications, innovative findings in this field have opened new windows in the treatment of patients.
体外成熟(IVM)是一种从窦状卵泡中提取未成熟卵母细胞并在实验室条件下使其成熟的方法。本综述试图提供卵母细胞体外成熟的当前知识和最新发现,并强调该过程中涉及的最重要因素。该综述基于文献报道和作者的经验。在IVM周期中,人绒毛膜促性腺激素(hCG)的给药时间取决于已确定直径约为10 - 12毫米的最大卵泡,以防止优势卵泡(DF)的有害影响。通过将hCG注射时间延长至38小时,可以获得更多体内成熟且具有分散卵丘细胞(CC)模式的卵母细胞。卵母细胞在体外成熟的最后几个小时内的生长对后续结果有深远影响。注射IVM卵母细胞必须在第一极体排出后至少延迟1小时。IVM结果表明,除多囊卵巢(PCO)(多囊卵巢和多囊卵巢综合征)病例外,单纯未成熟卵母细胞的妊娠率较低。此外,在非hCG触发的IVM后,子宫内膜质量在这方面可能起关键作用。不同类型成熟培养基的配方表明,它们通常添加了重组促卵泡生成素(FSH)和hCG。牛磺酸和钙作为囊胚培养基的独特成分,被认为对IVM培养基有价值。丙酮酸、三磷酸腺苷(ATP)和表皮生长因子(EGF)已被提议作为成熟培养基的添加剂。IVM不适用于40岁以上的女性。不同类别的患者可能是IVM的候选者。尽管过去对IVM结果不佳存在旧观念,且对IVM适应症持谨慎态度,但该领域的创新发现为患者治疗打开了新的窗口。